Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sabra Health Care REIT (SBRA)

Sabra closes $500 million unsecured term loan due 2030 and redeems 2026 notes

Neutral Impact 3 of 5 financing Written later

Sabra's operating partnership entered into a $500.0 million unsecured term loan on July 30, 2025, with an accordion feature that can raise total available borrowings to $1.0 billion. On July 31, 2025, the partnership redeemed all $500.0 million of its 5.125% Senior Notes due 2026, so the new loan refinances that debt.

Key points

  • Term loan of $500.0 million matures July 30, 2030; the accordion can increase total available borrowings to $1.0 billion, subject to terms.
  • Interest is SOFR-based or Base Rate plus a ratings-based margin of 0.800% to 1.600% for SOFR borrowings and 0.000% to 0.600% for Base Rate borrowings.
  • Interest rate swaps with $500.0 million notional fix the SOFR portion at a weighted average 3.44%, for an effective Term Loan rate of 4.64% through July 30, 2030.
  • The 2026 Notes were redeemed at 100.575% of principal plus accrued and unpaid interest.

The filing

CompanySabra Health Care REIT (SBRA)
Form8-K, current report
Filed with the SECJul 31, 2025, 4:06 PM ET
Accession number0001492298-25-000027

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.